Following the GT 6 Pro’s lead, the next-gen Watch D3 may feature a non-invasive diabetes risk assessment tool
Huawei is reportedly preparing to launch the third generation of its specialized health smartwatch, with a prominent Weibo leaker pointing to a release of the Huawei Watch D3 as early as Q2.
While hardware specifics remain unclear, the headline feature is expected to be non-invasive blood glucose monitoring—a breakthrough that would solidify Huawei’s position among those at the front of the medical-grade wearable race.
While the brand has expanded its TruSense branding across its entire portfolio, the D-series remains the cornerstone of its medical-grade ambitions. And according to this latest hint, the 2026 iteration looks set to tackle the holy grail of wearables: non-invasive blood glucose monitoring.
Credit: Weibo
Even with that potential nugget, though, the nature of the tracking is unknown. It may even simply be the same analysis of trends—rather than a direct measurement—that the brand debuted last month via the Watch GT 6 Pro.
However, we may find out soon. The info aligns with a broader rumor from the leaker that Huawei is planning a significant hardware event in April, where the Watch D3 would likely sit alongside a refreshed Watch Fit 5 series and a rumored Ultra variant.
Advertisement
Building on strong foundations
While the D3’s exact design (and existence, to be clear) is still unknown, it has a high bar to clear.
The current-gen Watch D2 earned a 4.5/5-star review from us for its health tracking—and for moving past the original Watch D design, which kind of looked like it was made for sick people.
If it arrives soon, we expect the Watch D3 to build on the HarmonyOS 6.0 foundation that rolled out to the D2 over the last year.
This software suite introduced the HealthMate interface, sophisticated HRV data for fatigue tracking, and single-measurement reminders designed to help hypertensive users establish a stable daily routine. We also expect a refinement of the signature micro-air pump and airbag system, which currently provides the most accurate wrist-based blood pressure readings on the market.
If the D3 can deliver on the glucose promises while maintaining the sleek, non-clinical aesthetic of the D2, it will remain the go-to pick for those managing complex health conditions.
